

### Validity Testing Information Part I

Laboratory Name: S.E.D. Medical Laboratories  
Address: 5601 Office Blvd NE ABR NM 87109  
Responsible Person: Martin J. Brady (Printed Name)

I certify that the answers and information provided are true and correct as of this date. Any false, fictitious, or fraudulent answers or information provided may violate Federal Law and could subject me to prosecution, monetary penalties, or both (Sec 18 U.S.C. 1001; 31 U.S.C. 3801-812).

Martin J. Brady  
Signature, Responsible Person

10/5/00  
Date

Martin J. Brady  
Printed Name, Responsible Person

**S.E.D. MEDICAL LABORATORIES**

**Toxicology**

5601 OFFICE BLVD NE; ALBUQUERQUE, NM 87109

The information contained in this FAX transmission is CONFIDENTIAL, and intended solely for the use of the individual or entity named on this transmittal form. If the reader of this FAX information is not the intended recipient or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution, copying, or unauthorized use of this communication is strictly prohibited.

If you have received this FAX information in ERROR, please notify the sender immediately by calling (800) 999-LABS, and returning the report to the sender at the address listed in the heading via the United States Postal Service. Thank-You.

TO: *Kenneth H. Davis, Jr.*

COMPANY: *RTI*

FAX# *919-541-7042*

FROM: **MARTIN BRADY**

DEPARTMENT: **TOXICOLOGY**

PHONE: **(505) 727-6334** FAX#: **(505) 727-6327**  
**(800) 999-5227 X 6334**

Number of Pages (Include Cover): *3*

Date Sent: *10/5/00*

NOTES:

*Original to follow.  
Validity Testing Information Part I*

## Validity Testing Information Part II

Conduct an audit of all DOT regulated specimens from the date your laboratory started validity testing. Summarize your findings in an Excel spread sheet in both hard copy and electronic format. Provide the following information in a separate column of the spreadsheet/audit for *each* DOT regulated specimen that was reported either adulterated or substituted:


- Specimen ID number
- Laboratory Accession Number
- Date of receipt
- Date reported
- Reported result (i.e., adulterated or substituted)
- Quantitative test result (e.g., actual creatinine concentration and specific gravity reading; actual pH reading; adulterant identity and its concentration if applicable)

*Note: Retain a copy of this information to ensure that you would be able to retrieve additional data.*

I certify that the answers and information provided are true and correct as of this date. Any false, fictitious, or fraudulent answers or information provided may violate Federal Law and could subject me to prosecution, monetary penalties, or both (Sec 18 U.S.C. 1001; 31 U.S.C. 3801-812).


  
\_\_\_\_\_  
Signature, Responsible Person

  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Printed Name, Responsible Person

**S.E.D. Medical Laboratories**  
**Validity Testing Information Part II**

REQUISITION NUMBER	ACCESSION NUMBER	DATE RECEIVED	DATE REPORTED	REPORTED AS	QUANTITATIVE TEST RESULT			
					pH	Creatinine in mg/dL	Specific Gravity	Nitrites in ug/mL



10/16/00


*Martin J. By* 10/16/00

**S.E.D. Medical Laboratories**  
**Validity Testing Information Part II**

REQUISITION NUMBER	ACCESSION NUMBER	DATE RECEIVED	DATE REPORTED	REPORTED AS	QUANTITATIVE TEST RESULT			
					pH	Creatinine in mg/dL	Specific Gravity	Nitrites in ug/mL

S.E.D. Medical Laboratories  
Validity Testing Information Part II

REQUISITION NUMBER	ACCESSION NUMBER	DATE RECEIVED	DATE REPORTED	REPORTED AS	QUANTITATIVE TEST RESULT			
					pH	Creatinine in mg/dL	Specific Gravity	Nitrites in ug/mL



**S.E.D. Medical Laboratories**  
**Validity Testing Information Part II**

REQUISITION NUMBER	ACCESSION NUMBER	DATE RECEIVED	DATE REPORTED	REPORTED AS	QUANTITATIVE TEST RESULT			
					pH	Creatinine in mg/dL	Specific Gravity	Nitrites in ug/mL



RESEARCH TRIANGLE INSTITUTE



National Laboratory Certification Program

December 13, 2000

296  
Mr. Martin J. Brady  
S.E.D. Medical Laboratories  
5601 Office Blvd.  
Albuquerque, NM 87109

Dear Mr. Brady:

The enclosed critique was developed from the inspection report associated with the November 01, 2000 specimen validity testing inspection of your laboratory under the National Laboratory Certification Program (NLCP). The laboratory's procedures were not in compliance with program guidance issued in Program Document 035 (September 28, 1998) and Program Document 037 (July 28, 1999). The laboratory must submit information to address the following issues raised:

Mr. Brady  
December 13, 2000  
Page 2 of 2

The laboratory must submit, within 30 calendar days of receipt of this letter, documentation to demonstrate that corrective actions have been implemented to address the issues listed in this correspondence. The laboratory must also review the enclosed critique and take all necessary corrective actions. In responding to these issues, please organize the material in your document in accordance with the sections and item numbers as listed in this correspondence. All corrective actions must be implemented within 30 days receipt of this correspondence and will be reviewed at the next inspection. ***Failure to comply may result in the laboratory's suspension to perform specimen validity testing on federally regulated specimens.***

If you have any questions or if we can be of further assistance, please call me at (919) 541-7265 or Dr. Michael Baylor at (919) 541-7043.

Sincerely,



Deborah J. Denson  
NLCP Technical Analyst

Enclosure

cc: Project Files/svt296

---

---

## NATIONAL LABORATORY CERTIFICATION PROGRAM

---

### Document Review and Critique

---

---

Laboratory I.D. Number: 0296  
Document No. Final

Laboratory: S.E.D. Medical Laboratories

Location: Albuquerque, NM

Document Reviewed:  Specimen Validity Testing Inspection Report

Date: 1 November 2000

---

---

A review of the National Laboratory Certification Program (NLCP) consensus inspection report has been completed. Issues identified during the inspection are described on the following pages. Evidence that appropriate remedial action has been taken is required for continued certification.

The following comments were noted, and appear in the same order as the corresponding questions in the Laboratory Inspection Report:

Section E. Standard Operating Procedures - Procedures Manual

---

Section F. Chain-of-Custody, Accessioning, and Security

---

Section G. Quality Control and Quality Assurance

---

Section I. Specimen Validity Tests

---

Section K. Records Audit

---

Section L. Certification and Reporting

January 11, 2001

received  
1/12/01 DP



Deborah J. Denson  
NLCP Inspection Analyst  
Research Triangle Institute  
3040 Cornwallis Rd.  
P.O. Box 12194  
Research Triangle Park, North Carolina 27709-2194

S.E.D. Medical Laboratories

5601 Office Blvd., NE  
Albuquerque, New Mexico 87109-5816  
505-727-6300 800-999-LABS  
Fax 505-727-6205

The enclosed is in response to your critique of our laboratory as a result of our special validity test inspection under the National Laboratory Certification Program (NLCP), which we received on December 14, 2000.

James E. Fantus  
President and CEO

Lanu Stoddart, MD  
Medical Director

Thomas A. Keith, MD

I. David Mones, MD

Scott Otteson, MD

Ellen J. Giampoli, MD

Emeritus:

S. Victor Savino, MD

David W. Dain, MD

Alan G. Engberg, MD

Robert M. List, MD

Nanci M. George  
Vice President, Marketing

Kari Young, CPA  
Vice President, Finance

Charley Newcomb, MS  
Chief Information Officer

Denise Ballou, MS, MT (ASCP)  
Director, Technical Operations

Liz Pratt, MT (ASCP)  
Director, Service Operations

Rebecca Falance, SPHR  
Director, Human Resources

Sincerely,

Martin J. Brady  
Director of Toxicology  
S.E.D. Medical Laboratories



# RESEARCH TRIANGLE INSTITUTE

National Laboratory Certification Program

January 23, 2001

0296  
Mr. Martin J. Brady  
S.E.D. Medical Laboratories  
5601 Office Blvd.  
Albuquerque, NM 87109

Dear Mr. Brady:

We have reviewed the material provided in your correspondence of January 11, 2001 submitted in response to issues raised during the November 01, 2000 specimen validity testing inspection of your laboratory as outlined in our correspondence of December 13, 2000. The information submitted by the laboratory appears to demonstrate that appropriate corrective actions have been completed to address the issues raised. The following is a review of the material submitted:



Mr. Brady  
January 23, 2001  
Page 2 of 2

Based upon our review of the material submitted, it appears that the laboratory is taking steps to ensure that its specimen validity testing procedures are in compliance with program guidance. All corrective actions must be implemented within 30 days of the receipt of this correspondence and will be reviewed during the next inspection. Failure to comply may result in the laboratory's suspension to perform specimen validity testing on federally regulated specimens.

If you have any questions or if we can be of further assistance, please call me at (919) 541-7265 or Dr. Michael R. Baylor at (919) 541-7043.

Sincerely,



Deborah J. Denson  
NLCP Technical Analyst

cc: Project Files/SVT296